These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 30095284)

  • 1. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.
    Burton T; Lapuerta P
    Future Oncol; 2018 Oct; 14(23):2361-2370. PubMed ID: 30095284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
    Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
    World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
    Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
    Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
    Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
    Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
    Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
    World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
    Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
    Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
    Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
    J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
    Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
    Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
    Cheng Y; Anthony L; Delcher C; Moga DC; Chauhan A; Huang B; Adams V
    Oncologist; 2023 Jun; 28(6):479-485. PubMed ID: 36994847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
    Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Gomez MJ; Del Olmo-García MI; Lorenzo I; Díaz JÁ; Canal N; De la Cruz G; Villabona C
    Clin Transl Oncol; 2021 Oct; 23(10):2046-2056. PubMed ID: 34109562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.
    Halperin DM; Huynh L; Beaumont JL; Cai B; Bhak RH; Narkhede S; Totev T; Duh MS; Neary MP; Cella D
    BMC Cancer; 2019 Mar; 19(1):274. PubMed ID: 30922252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.
    Shen C; Chu Y; Halperin DM; Dasari A; Zhou S; Xu Y; Yao JC; Shih YT
    Oncologist; 2017 Dec; 22(12):1451-1462. PubMed ID: 28642335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
    Baser O; Xie L; Pesa J; Durkin M
    J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
    Joish VN; Frech F; Lapuerta P
    Clin Ther; 2017 Dec; 39(12):2338-2344. PubMed ID: 29175096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.
    Cai B; Broder MS; Chang E; Yan T; Metz DC
    World J Gastroenterol; 2017 Oct; 23(40):7283-7291. PubMed ID: 29142475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Depression on Health and Medical Care Utilization and Expenses in US Adults With Migraine: A Retrospective Cross Sectional Study.
    Wu J; Davis-Ajami ML; Kevin Lu Z
    Headache; 2016 Jul; 56(7):1147-60. PubMed ID: 27350407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic burden of breakthrough seizures.
    Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
    Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.